



## **Pixium Vision and research partners report progress in multiple areas with IRIS<sup>®</sup> and PRIMA during ARVO 2017 World Conference**

- **IRIS<sup>®</sup> system shows highly significant correlation ( $p < 0.001$ ) between electrode stimulation site and visual percept location**
- **PRIMA system elicits visual perception, demonstrated via positive behavioral response in living animal models**

**Paris, May 3<sup>rd</sup>, 2017** – 7:30 CET - Pixium Vision (FR0011950641 - PIX), a company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, today announced its scientific program with multiple presentations of clinical and pre-clinical results at the Association for Research in Vision and Ophthalmology (ARVO) 2017 world congress in Baltimore 7 – 11 May, the main annual event for research and innovation in ophthalmology. The presentations consist in 4 poster presentations and 3 podium talks, including IRIS<sup>®</sup> retinotopic performance in human and latest insights into PRIMA's pre-clinical performance and safety results.

Regarding the IRIS<sup>®</sup> epi-retinal bionic vision system, results showed a highly significant correlation ( $p < 0.001$ ) between electrode stimulation position and perceived phosphene flash location in patient's visual field. These results from the IRIS<sup>®</sup> clinical study allow definition of stimulation strategies aiming to provide clinical benefit with the IRIS<sup>®</sup> system.

Regarding the PRIMA wireless sub-retinal photovoltaic implant, the multiple presentations include results from the Vision Institute in Paris, demonstrating positive behavioural response via elicited visual perception with PRIMA implant in a living non-human primate. Moreover, Stanford University team also presents positive behavioural results with prosthetic vision mediated by PRIMA implant in rats with retinal degeneration. These new pre-clinical data sets further strengthen Pixium Vision's file for first-in-human studies which is being assessed by regulatory bodies.

**Khalid Ishaque, CEO of Pixium Vision**, said: *"We are delighted to share the excellent advances made with both IRIS<sup>®</sup> and PRIMA, our two retinal bionic vision systems, with the global vision research community at ARVO. The research results with IRIS<sup>®</sup> in clinical study continue to add to clinical experience for improving patient outcomes and supporting commercialization activities following its regulatory approval in Europe. For PRIMA, our tiny wireless photovoltaic implant, the latest pre-clinical results presented at ARVO provide even greater support in planning and on-going dialogue with the regulatory bodies for the first human studies".*

The presentations on IRIS® and PRIMA include:

- **Retinotopy of percepts elicited by an IRIS® epi-retinal implant**  
*V. Bismuth et al.*  
Poster board #: B0546; Abstract Number: 4190 - B0546
- **Behavioral and electrophysiological characterization of photovoltaic subretinal implants in non-human primates**  
*P-H. Prevot et al.*  
Presentation Abstract Number: 4270 Paper Session Wed, May 10 - 12:30 – 12:45 Hall G
- **Behavioral assessment of photovoltaic subretinal prosthesis in rats with retinal degeneration**  
*H. Lorach et al.*  
Poster board #: B0558; Abstract Number: 4202 - B0558
- **Photovoltaic Subretinal Prosthesis with Pixel Sizes Down to 40 um**  
*E. Ho et al.*  
Presentation Abstract Number: 4269 Paper Session Wed, May 10 - 12:15 – 12:30 Hall G
- **Retinal spatiotemporal characteristics and contrast sensitivity with subretinal prosthesis**  
*X. Lei et al.*  
Poster board #: B0539; Abstract Number: 4183 - B0539
- **Optimization of pillar electrodes in subretinal prosthesis for enhanced proximity to target neurons**  
*T. Flores et al.*  
Poster board #: B0556; Abstract Number: 4200 - B0556
- **Animal studies of subretinal approach to prosthetic restoration of sight**  
*Daniel Palanker*  
Retinitis pigmentosa: Novel treatments and challenges Room 314 Sat, May 6 – 1:00pm – 4:30pm

To view Pixium Vision related abstracts please click here: [ARVO2017](#)

**Next event: Annual General Meeting – June 27<sup>th</sup>, 2017**

## Contacts

### Pixium Vision

Didier Laurens, CFO

[investors@pixium-vision.com](mailto:investors@pixium-vision.com)

+33 1 76 21 47 68



@PixiumVision

### Press Relations: Newcap Media

Annie-Florence Loyer - [afloyer@newcap.fr](mailto:afloyer@newcap.fr)

+33 1 44 71 00 12 / +33 6 88 20 35 59

Léa Jacquin - [ljacquin@newcap.fr](mailto:ljacquin@newcap.fr)

+33 1 44 71 20 41

## About ARVO, the Association for Research in Vision and Ophthalmology (<http://www.arvo.org/> )

ARVO is the largest and most respected eye and vision research organization in the world. Members include nearly 11,000 researchers from over 75 countries. About 45% of the attendees are from outside the U.S.

Mission: ARVO advances research worldwide into understanding the visual system and preventing, treating and curing its disorders.


This year the conference takes place in Baltimore USA from May 7-11.

## ABOUT PIXIUM VISION

Pixium Vision's Mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy. Pixium Vision's bionic vision systems are associated with a surgical intervention as well as a rehabilitation period.

The company is developing two bionic retinal implant systems. IRIS®II, the company first bionic system, obtained CE mark in July 2016. In parallel, Pixium Vision has recently completed the pre-clinical study phases for PRIMA, a sub-retinal miniaturized wireless photovoltaic implant platform, and is planning to initiate first-in-human trials.

Pixium Vision collaborates closely with academic and research partners spanning across the prestigious Vision research institutions including the Institut de la Vision in Paris, the Hansen Experimental Physics Laboratory at Stanford University, and Moorfields Eye Hospital in London. The company is EN ISO 13485 certified.

For more information, please visit:  [www.pixium-vision.com](http://www.pixium-vision.com);

And follow us on:  @PixiumVision;  [www.facebook.com/pixiumvision](https://www.facebook.com/pixiumvision)

 [www.linkedin.com/company/pixium-vision](https://www.linkedin.com/company/pixium-vision)

**PIX**  
**LISTED**  
**EURONEXT**



Pixium Vision is listed on Euronext Paris (Compartment C). Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.

Pixium Vision is included in the Euronext CAC All Shares index

Euronext ticker: PIX - ISIN: FR0011950641 – Reuters: PIX.PA – Bloomberg: PIX:FP

## Disclaimer:

*This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward looking statements.*

*Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise.*

*For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company's Registration Document filed with the AMF under number R16-033 on April 28, 2016 which can be found on the websites of the AMF - AMF ([www.amf-france.org](http://www.amf-france.org)) and of Pixium Vision ([www.pixium-vision.com](http://www.pixium-vision.com)).*

IRIS® is a trademark of Pixium-Vision SA